National Center for Complementary and Integrative Health (NCCIH)
nccih.nih.govTotal trials
222
Active
8
Phase 3
23
Total enrollment
41,002
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| (2R,6R)-Hydroxynorketamine | — | — | — | — | — | 1 | |
| Naproxen | — | — | — | — | — | 1 | |
| Pregabalin | — | — | — | — | — | 1 |
Next readouts
- 2029-12-31
- 2030-12-31
Top conditions
- HIV Infections17
- Pain14
- Depression12
- Healthy8
- Fibromyalgia7
- Obesity6
- Neoplasms6
- Osteoarthritis5
Frequently asked questions about National Center for Complementary and Integrative Health (NCCIH)
- How many clinical trials does National Center for Complementary and Integrative Health (NCCIH) have on ClinicalTrials.gov?
- National Center for Complementary and Integrative Health (NCCIH) is listed as the lead sponsor on 222 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Center for Complementary and Integrative Health (NCCIH)'s trials are in Phase 3?
- 23 of National Center for Complementary and Integrative Health (NCCIH)'s trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does National Center for Complementary and Integrative Health (NCCIH) focus on?
- National Center for Complementary and Integrative Health (NCCIH)'s most-studied conditions on ClinicalTrials.gov are HIV Infections, Pain, Depression, Healthy, Fibromyalgia.
- When are National Center for Complementary and Integrative Health (NCCIH)'s next clinical trial readouts?
- National Center for Complementary and Integrative Health (NCCIH) has 2 upcoming primary-completion readouts tracked here; the soonest is “Human Experimental Models of Pain (HEMP)”, expected around 2029-12-31.